REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Clinical trials for REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New bridge therapy aims to get more patients to lifesaving CAR-T treatment
Disease control Recruiting nowThis study is testing a drug called odronextamab to see if it can help control aggressive lymphoma long enough for patients to receive CAR-T cell therapy, a potentially curative treatment. The drug is given before the process to collect immune cells for CAR-T begins, with the goa…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New combo therapy aims to rally immune system against tough lymphomas
Disease control Recruiting nowThis study is testing a combination of two drugs, epcoritamab and ibrutinib, for adults with aggressive B-cell non-Hodgkin lymphoma that has come back or stopped responding to previous treatments. The goal is to find a safe and effective dose. One drug helps the body's own immune…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New bridge to a cancer cure: drug combo aims to get more patients to Life-Saving CAR-T
Disease control Recruiting nowThis study is testing a two-drug combination (golcadomide and rituximab) as a 'bridging therapy' for adults with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to control the cancer and improve patients' health so they can qualify fo…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New combo therapy aims to boost Cancer-Killing power of CAR-T
Disease control Recruiting nowThis early-phase study is testing the safety and effectiveness of a new drug called ST-067 when given alongside a personalized immune cell therapy (CAR-T) for patients with aggressive large B-cell lymphoma that has come back or not responded to other treatments. The goal is to se…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 17, 2026 13:08 UTC